Skip to main content
. 2023 Jul 19;15(1):2236265. doi: 10.1080/19420862.2023.2236265

Figure 3.

(A) Bispecific IL-18 surrogate agonists trigger IFN-γ production on PBMCs of multiple donors at a fixed concentration of 100 nM. (B) Selected bispecific IL-18 mimetics elicit a dose-dependent IFN-γ on PBMCs of multiple healthy donors with varying potencies.

Bispecific (1 + 1) surrogate agonists trigger IFN-γ release on PBMCs isolated from healthy donors.

(A) IFN-γ production of PBMCs stimulated with bsAbs at a fixed concentration of 100 nM or with (rh) IL-18 at 1 nM. Experiments were performed in the presence of 10 ng/mL (rh) IL-12. Graph shows box and whisker plots as superimpositions with dot plots of IFN-γ release of 10 different donors. ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05.IL18R_VHHα1β16 was used as negative control (given in red). Four leading candidates used for further characterization shown in green, purple, blue, and orange. (B) TOP4 candidates evoke a dose-dependent IFN-γ read-out on PBMCs in the presence of low dose (rh) IL-12 (10 ng/mL). IL18R_VHHα1β16 as negative control shown in red was used at a fixed concentration of 1 µM. Mean values ± SEM of 10 independent experiments p[,//’/l;\]=\][l; are shown.